Suppr超能文献

单硝酸异山梨酯与米索前列醇用于足月宫颈成熟的随机试验。

Randomized trial of isosorbide mononitrate versus misoprostol for cervical ripening at term.

作者信息

Chanrachakul B, Herabutya Y, Punyavachira P

机构信息

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

出版信息

Int J Gynaecol Obstet. 2002 Aug;78(2):139-45. doi: 10.1016/s0020-7292(02)00128-5.

Abstract

OBJECTIVES

To assess the adverse effects of isosorbide mononitrate (IMN) compared with misoprostol for cervical ripening at term.

METHODS

One hundred and seven women with term pregnancies referred for induction of labor with Bishop scores of 6 or less were randomly allocated to receive either a 40-mg IMN tablet vaginally (n = 55) or 50 microg misoprostol vaginally (n = 52) every 6 h for a maximum of three doses. They were sent to the labor ward for amniotomy or oxytocin if either their Bishop scores were more than 6 or their cervices were not ripe 24 h after the treatment. Adverse effects, progress, and outcomes of labor were assessed.

RESULTS

Isosorbide mononitrate was associated with fewer adverse effects especially uterine tachysystole (0 vs. 19.2%, P < 0.01) and hyperstimulation (0 vs. 15.4%, P < 0.01). The time from start of medication to vaginal delivery in IMN group was significantly longer (25.6 +/- 6.1 vs. 14 +/- 6.9 h, P < 0.01). Oxytocin was needed in 51 women (92%) of the isosorbide mononitrate group and six women (11%) of the misoprostol group (P < 0.001). The cesarean rate was not significantly different between the groups, but the major indications were different: dystocia (45%) in the IMN group vs. persistent non-reassuring fetal heart rate pattern (56%) in the misoprostol group.

CONCLUSIONS

Cervical ripening with IMN resulted in fewer adverse effects, but was less effective than misoprostol.

摘要

目的

评估单硝酸异山梨酯(IMN)与米索前列醇用于足月宫颈成熟的不良反应。

方法

107例足月妊娠且 Bishop 评分≤6分的产妇被随机分配,分别接受阴道放置40mg的IMN片(n = 55)或每6小时阴道放置50μg米索前列醇(n = 52),最多3剂。若治疗后24小时Bishop评分>6分或宫颈仍未成熟,则将她们送入产房行人工破膜或使用缩宫素。评估不良反应、产程进展及分娩结局。

结果

单硝酸异山梨酯的不良反应较少,尤其是子宫收缩过速(0%对19.2%,P<0.01)和子宫过度刺激(0%对15.4%,P<0.01)。IMN组从开始用药至阴道分娩的时间显著延长(25.6±6.1小时对14±6.9小时,P<0.01)。单硝酸异山梨酯组51例(92%)产妇需要使用缩宫素,米索前列醇组6例(11%)产妇需要使用缩宫素(P<0.001)。两组剖宫产率无显著差异,但主要指征不同:IMN组为难产(45%),米索前列醇组为持续性胎儿心率异常(56%)。

结论

IMN用于宫颈成熟不良反应较少,但效果不如米索前列醇。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验